Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.42 |
| ▸ | BRAF | P15056 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959948 | 0.90 | MAPK14 (0.42) | MAPK14BRAFCYP1A2MAPK13MAPT | |
| SCHEMBL2958673 | 0.87 | MAPK14 (0.48) | MAPK14CYP1A2MAPK13MAPTLMNA | |
| SCHEMBL2953305 | 0.87 | MAPK14 (0.42) | MAPK14CYP1A2MAPK13MAPTLMNA | |
| SCHEMBL2961525 | 0.86 | CHRNA7 (0.45) | MAPK14CYP1A2MAPK13MAPTLMNA | |
| SCHEMBL2959949 | 0.86 | MAPK14 (0.47) | MAPK14CYP1A2MAPK13MAPTLMNA | |
| SCHEMBL2959430 | 0.85 | MAPK14 (0.45) | MAPK14BRAFPTK2B | |
| SCHEMBL2958959 | 0.85 | MAPK14 (0.46) | MAPK14CYP1A2MAPK13MAPTLMNA | |
| SCHEMBL2957789 | 0.85 | LMNA (0.49) | MAPK14CYP1A2MAPK13MAPTLMNA | |
| SCHEMBL2957020 | 0.85 | MAPK14 (0.47) | MAPK14CYP1A2MAPK13MAPTLMNA | |
| SCHEMBL2961536 | 0.85 | MAPK14 (0.44) | MAPK14CYP1A2MAPK13MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767674-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2010-08-03 | — | — | US | disclosed |
| US-20080306068-A1 | Suppression cytokines, tumor necrosis factor | ELI LILLY AND COMPANY (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1761520-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306068-A1 | Suppression cytokines, tumor necrosis factor | TNF, TNFRSF1A, IL2 | MAPK14 436/4885BRAF 289/4885CYP1A2 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.